Intramuscular, SubcutaneousActive immunisation against measles, mumps and rubellaAdult: 0.5 mL as a single dose via IM or SC inj; a 2nd dose may be given at least 28 days after the 1st dose in accordance with the local guidelines. For post-exposure prophylaxis against measles: Administer within 72 hours after exposure. Recommendations on immunisation schedules and usage during outbreaks may vary between individual products or among countries (refer to specific product or local official guidelines).
Child: ≥12 months Primary immunisation: 0.5 mL for 2 doses via IM or SC inj, the 1st dose may be given at 12-15 months of age and the 2nd dose at 4-6 years of age. The 2nd dose may be given before 4 years of age, provided that there is a minimum interval of 28 days between the doses. If the vaccine is given before 12 months of age, revaccination is recommended starting at 12-15 months of age. For post-exposure prophylaxis against measles: Administer within 72 hours after exposure. Recommendations on immunisation schedules, approved age groups, and usage during outbreaks may vary between individual products or among countries (refer to specific product or local official guidelines).
|
|
|
Reconstitute the lyophilised vaccine vial with the supplied pre-filled syringe, vial, or ampoule containing the diluent. For vaccine with diluent in a pre-filled syringe, slowly inject the whole content of the diluent from the pre-filled syringe into the lyophilised vaccine vial. For vaccine with diluent in a vial or ampoule, withdraw the whole content of the diluent from the vial or ampoule, then inject it slowly into the lyophilised vaccine vial. Vaccine vial may be shaken or gently agitated to dissolve the powder completely. Instructions on preparation of the vaccine may vary between individual products (refer to detailed product guidelines).
|
Hypersensitivity. Active untreated TB; active febrile illness (fever >38.5°C); blood dyscrasias or any malignant neoplasms affecting the bone marrow or lymphatic systems (e.g. leukaemia, lymphoma); family history of congenital or hereditary immunodeficiency (unless immune competence can be established). Severely immunocompromised patients, including those with severe humoural or cellular (primary or acquired) immunodeficiency. Pregnancy. Contraindications may vary between individual products (refer to specific product guidelines).
|
Patient with history of hypersensitivity reaction following egg ingestion; personal or family history of seizure disorder; history of cerebral injury or any other conditions in which stress due to fever should be avoided; thrombocytopenia or bleeding disorder. Delay vaccination for at least 3 months after blood or plasma transfusion and human immunoglobulin administration (refer to local official guidelines). Children. Lactation.
|
Significant: Anaphylactoid or hypersensitivity reactions, febrile seizures, syncope, thrombocytopenia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
General disorders and administration site conditions: Fever (≥38.3°C), inj site reactions (e.g. erythema, pain, swelling, burning, stinging).
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Arthralgia, arthritis.
Psychiatric disorders: Irritability, abnormal crying.
Respiratory, thoracic and mediastinal disorders: URTI, rhinorrhoea.
Skin and subcutaneous tissue disorders: Rash, urticaria.
|
|
|
Women of childbearing potential must avoid pregnancy for 1 month after vaccination.
|
Monitor for syncope and anaphylaxis for 15 minutes after vaccination.
|
Concomitant use with immunoglobulins may interfere with the expected immune response.
|
May result in temporary depression of tuberculin skin sensitivity causing interference with tuberculin test; the test may be given before vaccination, simultaneously but at different sites on the same day, or 4-6 weeks after vaccination.
|
Description:
Mechanism of Action: Measles, mumps and rubella vaccine is a live, attenuated combination vaccine. It promotes active immunity against diseases caused by measles, mumps and rubella viruses.
|
Store between 2-8°C. Do not freeze. Protect from light. Reconstituted vaccine may be stored between 2-8°C for up to 8 hours. Do not freeze. Protect from light. Storage recommendations may vary between individual products (refer to specific product guidelines).
|
|
|
J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.
|
Brayfield A, Cadart C (eds). Measles, Mumps, and Rubella Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/06/2024. GlaxoSmithKline NZ Limited. Priorix Powder for Injection with Diluent data sheet 22 November 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 05/06/2024. Joint Formulary Committee. Measles, Mumps and Rubella Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/06/2024. M-M-R II Vaccine (Merck Sharp & Dohme [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 05/06/2024. M-M-R II Vaccine Live Injection, Powder, Lyophilized, for Suspension (Merck Sharp & Dohme LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/06/2024. M-M-Rvax Pro Powder and Solvent for Suspension for Injection (Merck Sharp & Dohme [UK] Limited). MHRA. https://products.mhra.gov.uk. Accessed 05/06/2024. Measles, Mumps, and Rubella Virus Vaccine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/06/2024. Measles/Mumps/Rubella Vaccines, MMR. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 05/06/2024. Priorix Powder and Solvent for Solution for Injection (GlaxoSmithKline Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 28/06/2024. Priorix Powder and Solvent for Solution for Injection in a Pre-filled Syringe (SmithKline Beecham Limited Trading as GlaxoSmithKline UK). MHRA. https://products.mhra.gov.uk. Accessed 28/06/2024.
|
Sign Out
